Aileron Therapeutics, Inc. announced that it has expanded its senior management team with the appointment of Evan Lippman as the company's first Chief Financial and Business Officer. Prior to joining Aileron, Mr. Lippman was Senior Vice President at EMD Serono.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.09 USD | +3.69% | -2.22% | +1.36% |
01/07 | Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell 3000E Index | CI |
01/07 | Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell Microcap Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.36% | 64.41M | |
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |
- Stock Market
- Equities
- ALRN Stock
- News Aileron Therapeutics, Inc.
- Aileron Therapeutics, Inc. Appoints Evan Lippman as Chief Financial and Business Officer